A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.
about
Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questionsOligodendroglioma: pathology, molecular mechanisms and markersContributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zonePrognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastomaAssessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.MGMT promoter methylation correlates with an overall survival benefit in Chinese high-grade glioblastoma patients treated with radiotherapy and alkylating agent-based chemotherapy: a single-institution study.Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trialMGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma responseAltered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations.Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.MGMT testing allows for personalised therapy in the temozolomide era.MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-statusIdentification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.Personalized treatment strategies in glioblastoma: MGMT promoter methylation status.Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients.Influence of promoter/enhancer region haplotypes on MGMT transcriptional regulation: a potential biomarker for human sensitivity to alkylating agents.Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing.Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma.Alteration in the expression of MGMT and RUNX3 due to non-CpG promoter methylation and their correlation with different risk factors in esophageal cancer patients.The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).MGMT promoter methylation in non-neoplastic brain.Effect of O6-methylguanine-DNA methyltransferase methylation in medulloblastoma.Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.Prognosis of glioblastoma with faint MGMT methylation-specific PCR product.Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients.MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations.A 4-miRNAs signature predicts survival in glioblastoma multiforme patients.MGMT promoter methylation status: time for a frank discussion.Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression.Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.GSK3β‑mediated Ser156 phosphorylation modulates a BH3‑like domain in BCL2L12 during TMZ‑induced apoptosis and autophagy in glioma cells.Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas.MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma
P2860
Q26795767-E9726B70-18E5-478B-963D-987925E5957FQ27002448-AAB42CED-AAA0-47D0-B088-2A54ED7B26A1Q28251767-4FC2F4C5-CD66-4312-9488-46FCBF9776BEQ28731328-BC2B7B7C-29AD-4255-866D-45E49914A62EQ30836702-61791A6D-A2D4-41D6-BFAB-BDBA7BC2A400Q34166477-CDBB0B8D-20CF-4E0C-8653-A0A114E6277AQ34500050-3D13DEDC-6713-45A8-9ED1-C30A7C4D5F48Q34525704-4E1026E3-C724-41D2-B2D0-592B13C3693DQ34625644-B8A814F5-9027-467A-8478-D27297088892Q35110170-173012E0-6183-49CA-AD1E-D21B139EAF4CQ35787908-F71035F6-19B0-4DD0-9A3B-DA7360CEE434Q35827916-A38F003B-9B1C-480E-84F1-AC2465787C87Q36240860-597BD94C-3695-4C78-B572-2262F2493E93Q36486875-5D570D5E-E1F7-4BA8-967B-971453D69C21Q36627170-2CF51AA9-A8F8-46FD-A57F-FB64BC1E59D1Q37221207-FB124765-E2CD-4C3E-A726-D1B30299B06EQ37526270-477633C5-5FE1-4F1D-9353-1FBB55ABED85Q37616073-8ED41BF8-9EB4-4C02-A86D-F69CCB5AAC6AQ38225830-68098F44-4F5C-40CE-9B17-634962D20958Q38836820-6D9C44B7-DF51-4AC0-ACA8-2121DE186AD8Q39206459-6046D34B-3EB1-4FBD-93E2-52E4E525B5C1Q39876681-95C65909-1387-4EA4-81F9-7AE512CB6E81Q40216898-D65FF28B-F9D2-49C5-945C-5232FE141526Q41009177-0DA623FC-D78D-4AB3-B931-C8DCAF3CE5ECQ41282384-E630D8A4-77D7-49BC-959A-D076CA34B865Q44440342-0617BDF2-8CC6-407D-9E7B-946C9A3BD252Q47128186-167D22D0-CED6-46FD-B83B-821E75383487Q47804454-EC3DF481-C532-4BB0-8240-6276D71D7804Q48137109-40F15DE4-0E9A-4457-8BCF-42A50361E2D0Q48797026-AE1FC404-7006-4622-B1E6-E86C9CCD09ACQ48824616-C07C20FA-54AE-4558-9A76-1871CFF7F6CEQ50225594-E3CDB740-09B9-4729-B8FD-54A4D00373C2Q50611672-92559A6B-FDD5-425C-B7EA-BB427CE6243DQ52150588-5D2CB315-E19D-4AC2-8327-8CAC167680A6Q53739720-41686D38-5BFD-4E53-B712-113FAAB4FD31Q54110692-0B068CF5-0C5E-4E01-B529-6C63DABF44AEQ55460981-7011901C-845C-4D14-AAF3-27EF9053C2EFQ56828332-E720F226-D39B-4C19-8B5C-BDF517374C70
P2860
A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A distinct region of the MGMT ...... blastoma cells and xenografts.
@en
A distinct region of the MGMT ...... blastoma cells and xenografts.
@nl
type
label
A distinct region of the MGMT ...... blastoma cells and xenografts.
@en
A distinct region of the MGMT ...... blastoma cells and xenografts.
@nl
prefLabel
A distinct region of the MGMT ...... blastoma cells and xenografts.
@en
A distinct region of the MGMT ...... blastoma cells and xenografts.
@nl
P2093
P2860
P1476
A distinct region of the MGMT ...... oblastoma cells and xenografts
@en
P2093
Danita M Pearson
Deborah S Malley
Koichi Ichimura
Sylvia Kocialkowski
Vincent Peter Collins
P2860
P2888
P304
P356
10.1007/S00401-011-0803-5
P50
P577
2011-02-03T00:00:00Z